Protagonist Therapeutics, Inc.
PTGX
$44.27
-$1.00-2.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -65.34% | 448.54% | 221.61% | 223.50% | 215.64% |
| Total Depreciation and Amortization | -12.64% | -12.59% | -3.89% | 0.75% | -2.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 24.22% | 15.09% | 13.75% | 6.84% | 9.42% |
| Change in Net Operating Assets | 196.29% | -528.41% | 583.15% | 527.95% | -3,239.06% |
| Cash from Operations | 632.15% | 362.19% | 293.80% | 297.19% | 39.59% |
| Capital Expenditure | -97.15% | -122.50% | -61.21% | -65.79% | -58.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -844.46% | -671.37% | -1,418.29% | -260.67% | -139.67% |
| Cash from Investing | -829.85% | -662.86% | -1,455.90% | -262.08% | -140.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -79.95% | -84.55% | -86.60% | -66.18% | 435.91% |
| Repurchase of Common Stock | 62.25% | 21.98% | 21.98% | 22.18% | -1,144.12% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -80.10% | -84.83% | -86.89% | -66.43% | 432.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -173.34% | -246.73% | -227.92% | 4.44% | 53.66% |